Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine
Date
2016Language
en
Sujet
Résumé
Abstract: Background: Parapneumonic effusions in children are usually associated with pneumococcal infections. In Greece, the 7-valent pneumococcal conjugate vaccine was replaced by higher-valent pneumococcal conjugate vaccines (PCVs); 10-valent was introduced in May 2009 and 13-valent (PCV13) in June 2010. Since July 2010, PCV13 has been the most commonly used PCV. In a study conducted at the University General Hospital of Larissa, Central Greece, from January 2012 to January 2016, 85.7% of children born after the implementation of PCV13 and aged 24–59 months had received the complete series (3 + 1 immunization schedule) of PCV13. Methods: We studied all paediatric community-acquired pneumonia cases with empyema hospitalized at the University General Hospital of Larissa from January 2008 to January 2016. Results: There were 30 cases of parapneumonic empyema. Among 27 empyema cases of known aetiology, 19 (70.4%) were due to Streptococcus pneumoniae (identifiable serotypes 3, 19A, 7F, and 9N/L). After September 2011, no more cases caused by serotypes 7F and 19A were observed, whereas serotype 3 emerged as the predominant pathogen of pneumococcal empyema (9 of 11 cases). Serotype 3 continued to cause empyema despite vaccination with PCV13 either fully with a 3 + 1 schedule (n = 3) or with one booster dose at the age of 21 months (n = 1). Conclusion: In Central Greece during the first five years of high coverage with PCV13, serotype 3 was the only PCV13 serotype that clearly persisted in children with empyema. © 2016 Society for Scandinavian Journal of Infectious Diseases.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Molecular surveillance of pneumococcal carriage following completion of immunization with the 13-valent pneumococcal conjugate vaccine administered in a 3 + 1 schedule
Syrogiannopoulos G.A., Grivea I.N., Moriondo M., Nieddu F., Michoula A.N., Calabrese M.R., Anthracopoulos M., Azzari C. (2021)In a cross-sectional study, with the use of molecular methods, we aimed to gain insight into oropharyngeal pneumococcal colonization over time in 1212 Greek children recruited in general pediatric settings throughout the ... -
Pneumococcal meningitis in Greece: A retrospective serotype surveillance study in the post-PCV13 era (2010–2020)
Xirogianni A., Marmaras N., Georgakopoulou T., Papandreou A., Simantirakis S., Magaziotou I., Eliades A., Getsi V., Anastasiou-Katsiardani A., Staikou E., Markou F., Argyrοpoulou A., Vlachaki G., Chronopoulou G., Pangalis A., Liakopoulou T., Michos A., Spoulou V., Lagona E., Panagiotakopoulos G., Petinaki E., Mantadakis E., Roilides E., Galanakis M., Papaevangelou V., Tsolia M., Tzanakaki G. (2022)Background: As Greece is a country which has introduced the 13-valent pneumococcal conjugate vaccine (PCV13) both in the infant and in the adult immunization programs, the aim of the study was to investigate age-specific ... -
Are younger COPD patients adequately vaccinated for influenza and pneumococcus?
Gogou E., Hatzoglou C., Zarogiannis S.G., Siachpazidou D., Gerogianni I., Kotsiou O.S., Varsamas C., Gourgoulianis K.I. (2022)Influenza and pneumococcal pneumonia are major causes of increased morbidity and mortality among elderly and COPD patients. Vaccines against influenza and pneumococcus are recommended for COPD patients according to GOLD ...